|Bid||36.75 x 1000|
|Ask||37.61 x 3100|
|Day's Range||37.28 - 38.13|
|52 Week Range||26.42 - 41.00|
|Beta (3Y Monthly)||0.88|
|PE Ratio (TTM)||31.34|
|Earnings Date||Apr 23, 2019 - Apr 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.07|
A Food and Drug Administration probe into chemotherapy drug paclitaxel is testing the waters for medical device companies SurModics, Boston Scientific, Medtronic and Becton Dickinson.
The use of Abbott's (ABT) HeartMate 3 pump can efficiently prolong life -term and improve the quality of life for advanced heart failure patients.
Medtronic's (MDT) clinical study data shows that the low-risk aortic stenosis patients have special characteristics as they tend to be younger and active compared with the higher-risk equivalents.
The positive result regarding Boston Scientific's (BSX) LUMINIZE RF Balloon Catheter is expected to help the company further advance with the procedures to clinch a CE Mark for the instrument.
All three major indexes closed in positive territory, despite reports that a meeting between President Donald Trump and Chinese President Xi Jinping may not happen until June. Investors are feeling relatively upbeat as they await news from global central banks this week, including the Federal Reserve on Wednesday. The Dow Jones Industrial Average rose 65.23 points, or 0.3%, to 25,914.1, while the S&P 500 ticked up 10.46 points, or 0.4%, to 2,832.94 and the Nasdaq Composite added 25.95 points, or 0.3%, to 7,714.48.
The news around paclitaxel is clearly negative and likely to meaningfully limit Eluvia sales, the analyst said. The FDA said Friday that it notified doctors that stents coated with the common cancer chemotherapy drug paclitaxel may be associated with a higher incidence of death in patients.
LISBON, Portugal and MARLBOROUGH, Mass., March 17, 2019 /PRNewswire/ -- Boston Scientific Corporation (BSX) announced data from the AF-FICIENT I study during a late-breaking clinical trial session today at EHRA 2019, the annual congress of the European Heart Rhythm Association in Lisbon, Portugal. Patients with arrhythmias such as AF are often treated with anti-arrhythmic drugs as well as cardiac ablation.
Receipt of the CE Mark followed by a limited launch of the WATCHMAN FLX device in Europe is likely to drive top-line contributions from Boston Scientific's (BSX) IC suite.
Boston Scientific Corp NYSE:BSXView full report here! Summary * Perception of the company's creditworthiness is positive * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for BSX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BSX. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold BSX had net inflows of $4.14 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator. BSX credit default swap spreads are near the lowest level of the last one year and indicate improvement in the market's perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The longest bull market in U.S. history turned 10 this past weekend. Here are the Massachusetts public companies that have gained the most in value over the past decade.
MARLBOROUGH, Mass. , March 11, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at EHRA 2019, the annual congress of the European Heart Rhythm ...
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Just a dozen ETFs hit record highs on Friday. Extending its 2019 gains to 15%, the iShares US Medical Devices ETF (NYSEArca: IHI) was one of the ETFs hitting all-times on Friday. That as the broader healthcare ...
Health-care stocks are trailing the S&P 500, but investors could find profits in some medical device plays, says stock-picking expert Matt Maley.
The most recent earnings release Boston Scientific Corporation's (NYSE:BSX) announced in December 2018 confirmed that the company benefited from a significant tailwind, more than doubling its earnings from the priorRead More...
NEW YORK, Feb. 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
MARLBOROUGH, Mass. , Feb. 27, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the Cowen and Company 39 th Annual Healthcare Conference on Wednesday, March 13, 2019 in ...
MARLBOROUGH, Mass., Feb. 25, 2019 /PRNewswire/ -- Boston Scientific Corporation (BSX) completed a public offering of $4.3 billion aggregate principal amount of its senior notes. The public offering consists of $850 million of 3.450% notes due 2024, $850 million of 3.750% notes due 2026, $850 million of 4.000% notes due 2029, $750 million of 4.550% notes due 2039 and $1.0 billion of 4.700% notes due 2049. The Company intends to use the net proceeds from the offering to (i) finance a portion of its previously announced proposed acquisition of BTG plc (the "BTG Acquisition"), (ii) redeem its 6.000% notes due January 2020 and its 2.850% notes due May 2020 (collectively, the "2020 Notes"), of which $850 million aggregate principal amount and $600 million aggregate principal amount, respectively, were outstanding as of the date of the aforementioned offering, (iii) repay amounts outstanding under its $1.0 billion Term Loan facility maturing August 2019, which bore interest at an annual rate of LIBOR plus 0.65%, (iv) repay other short term debt and (v) pay related fees, expenses and premiums.
MARLBOROUGH, Mass. , Feb. 21, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $4.3 billion aggregate principal amount of its senior notes under ...
Moody's Investors Service ("Moody's") assigned a Baa2 rating to the new senior unsecured notes offering of Boston Scientific Corporation ("Boston Scientific"). There are no changes to Moody's existing ratings of Boston Scientific including the Baa2 senior unsecured long-term rating and the Prime-2 short-term rating. Boston Scientific's Baa2 senior unsecured ratings reflects its meaningful scale in the medical device industry with revenues of approximately $10 billion.
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Revenue and EPS growth trajectoryIn its fourth-quarter earnings press release, Boston Scientific (BSX) reported revenues of $9.82 billion for fiscal 2018, a YoY rise of
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Margin guidanceIn the company’s fourth-quarter earnings conference call, Boston Scientific (BSX) has guided for an adjusted gross margin of 72%–73% for fiscal 2018,